Last-Resort hope: new drug offered to lymphoma patients with no options left
NCT ID NCT05619367
First seen Jan 02, 2026 · Last updated May 06, 2026 · Updated 20 times
Summary
This program gives people with certain types of lymphoma (like follicular lymphoma or diffuse large B-cell lymphoma) who have tried all other treatments access to an experimental drug called odronextamab. The goal is to provide a possible treatment option when no others are available. Participants receive the drug under a compassionate use policy, meaning it is not yet fully approved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.